• 1.

    General Chapter <795> Pharmaceutical Compounding—Nonsterile Preparations. In: United States Pharmacopeia and National Formulary (USP 43-NF 38). Revised January 1, 2014. Rockville, MD: The United States Pharmacopeia Convention Inc; 2020.

  • 1.

    Proposed Revisions to <795> Pharmaceutical Compounding – Nonsterile Preparations. The United States Pharmacopeia Convention Inc; 2021. Available at: https://go.usp.org/l/323321/2021-08-31/5kmcjf/323321/1630438802OI493yjz/BUD_Scientific_Rationale_for_the_2021_Proposed_Revisions_to__795_.docx. Accessed November 15, 2021.

  • 1.

    Pancorbo SA, Campagna KD, Devenport JK, et al.Task force report of competency statements for pharmacy practice. Am J Pharm Educ. 1987; 51:196–206.

    • Search Google Scholar
    • Export Citation
  • 2.

    Allen LV Jr. Establishing and marketing your extemporaneous compounding service. US Pharm. 1990; 15(Dec):74–7.

  • 3.

    Remington's pharmaceutical sciences. 18th ed. Gennaro AR, ed. Easton, PA: Mack Publishing; 1990; 1630–1, 1658, 1660.

  • 4.

    The United States Pharmacopeia, 22nd rev., and The National Formulary, 17th ed. Rockville, MD: The United States Pharmacopeial Convention; 1989.

    • Search Google Scholar
    • Export Citation
  • 5.

    USP DI Volume III: Approved drug products and legal requirements. 14th ed. Rockville, MD: The United States Pharmacopeial Convention; 1994.

    • Search Google Scholar
    • Export Citation
  • 6.

    USP DI Volume I: Drug information for the health care professional. 14th ed. Rockville, MD: The United States Pharmacopeial Convention; 1994.

    • Search Google Scholar
    • Export Citation
  • 7.

    29 §C.F.R. 1910. 1200(1990).

  • 8.

    ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990; 47:1033–49.

  • 9.

    Feinberg JL. Complying with OSHA's Hazard Communication Standard. Consult Pharm. 1991; 6:444, 446, 448.

  • 10.

    Myers CE. Applicability of OSHA Hazard Communication Standard to drug products. Am J Hosp Pharm. 1990; 47:1960–1.

  • 11.

    21 C.F.R. §211.137.

  • 12.

    Connors KA, Amidon GL, Stella VJ. Chemical stability of pharmaceuticals: a handbook for pharmacists. 2nd ed. New York: Wiley; 1986.

  • 13.

    American Society of Hospital Pharmacists. ASHP guidelines on preventing medication errors in hospitals. Am J Hosp Pharm. 1993; 50:305–14.

    • Search Google Scholar
    • Export Citation
  • 14.

    Fitzgerald WL Jr. The legal authority to compound in pharmacy practice. Tenn Pharm. 1990; 26(Mar):21–2.

  • 1.

    Associated Press. Pittsburgh woman loses eye to tainted drugs; 12 hurt. Baltimore Sun. 1990; Nov 9:3A.

  • 2.

    Associated Press. Eye drop injuries prompt an FDA warning. N Y Times. 1990; 140(Dec 9):39I.

  • 3.

    Jeglum EL, Rosenberg SB, Benson WE. Preparation of intravitreal drug doses. Ophthalmic Surg. 1981; 12:355–9.

  • 4.

    Reynolds LA. Guidelines for preparation of sterile ophthalmic products. Am J Hosp Pharm. 1991; 48:2438–9.

  • 5.

    Reynolds LA, Closson R. Ophthalmic drug formulations. A handbook of extemporaneous products. Vancouver, WA: Applied Therapeutics; 1993.

  • 6.

    The United States Pharmacopeia, 22nd rev., and The National Formulary, 17th ed. Rockville, MD: The United States Pharmacopeial Convention; 1989:1692–3.

  • 7.

    Allen LV. Indomethacin 1% ophthalmic suspension. US Pharm. 1991; 16(May):82–3.

  • 8.

    American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990; 47:1033–49.

    • Search Google Scholar
    • Export Citation
  • 9.

    OSHA work-practice guidelines for personnel dealing with cytotoxic (antineoplastic) drugs. Am J Hosp Pharm. 1986; 43:1193–204.

  • 10.

    Ansel HC, Popovich NG. Pharmaceutical dosage forms and drug delivery systems. 5th ed. Philadelphia: Lea & Febiger; 1990:354–7.

  • 11.

    Stolar MH. Expiration dates of repackaged drug products. Am J Hosp Pharm. 1979; 36:170. Editorial.

  • 12.

    Remington's pharmaceutical sciences. 19th ed. Gennaro AR, ed. Easton, PA: Mack Publishing; 1990:1581–959.

Vancomycin Hydrochloride Ophthalmic Solution 31 mg/mL

in Extemporaneous Formulations
Authors: Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
DOI:
https://doi.org/10.37573/9781585286522.200
Free access

INGREDIENTS:

Vancomycin hydrochloride 500 mg injection1 vial
Sterile water for injection5 mL
Artificial tearsQSAD: 15 mL

EQUIPMENT AND SUPPLIES:

Laminar flow hood, 3 × 18-G needles, 3 × 5-mL syringes, 1 × 0.22-µm filter needle

PREPARATION DETAILS:

Must be prepared in compliance with USP <797>.

  1. Reconstitute injectable powder with 5 mL of sterile water for injection.

  2. Withdraw 4.6 mL of artificial tears from the 15-mL ophthalmic bottle and discard.

  3. Withdraw 4.6 mL of vancomycin injectable solution using a 5-mL syringe.

  4. Change to a 0.22-µm filter needle.

  5. Transfer the vancomycin solution into the ophthalmic bottle with the remaining artificial tears.

  6. Shake well to mix.

Quality-Control Procedures — Visually inspect for physical appearance of formulation and container closure integrity (no leakage, cracks in container, or improper seals).

Labeling Requirements — Extemporaneously compounded preparation. For ophthalmic use only. Store at room temperature or refrigerate.

Storage Conditions/Stability — Store at room temperature or refrigerate. Stable for 10 days when refrigerated and 7 days when stored at room temperature.

STABILITY STUDY DETAILS:

Study Container Type — Ophthalmic dropper bottle

Referenced Manufacturers — Vancomycin hydrochloride injection (Vancocin, Eli Lily & Co); sterile water for injection (McGaw); artificial tears (Tears Naturale, Alcon Laboratories, Inc).

Stability-Indicating Study — Yes

Footnote — Artificial tears contain 0.3% hydroxypropyl methylcellulose, 0.1% dextran 70, 0.01% benzalkonium chloride, and 0.05% edetate disodium.

REFERENCES

  • 1.

    Fuhrman LC Jr, Stroman RT. Stability of vancomycin in an extemporaneously compounded ophthalmic solution. Am J Health Syst Pharm. 1998;55(13):1386–1388.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Osborn E, Baum JL, Ernst C, et al.The stability of ten antibiotics in artificial tear solutions. Am J Ophthalmol. 1976;82(5):775–780.